

September 2024

News and highlights keeping you informed as we work together to accelerate life-changing treatments for people with progressive MS worldwide.

The Alliance at ECTRIMS 2024

[Alliance members took the opportunity to meet in person to move Alliance work forward](#)

During the ECTRIMS Annual Congress, which took place September 18-20, two Alliance work teams met in person to discuss progress to date, and to align on the scientific roadmap that will move the Alliance forward for the next three to five years.

The Industry Forum first met to discuss prospective initiatives for 2025. Then, the Industry Forum met jointly with the Scientific Steering Committee to review the progress we've made over our current strategic plan, and then reviewed and discussed refreshing the strategic plan and scientific roadmap for the Alliance for 2025-2030. The team did a deep dive into planned work, discussed the biggest areas of unmet need within progressive MS, and determined which are the most important to focus on in the coming years.



Breaking News: Tolebrutinib Delays Time to Disease Progression in Secondary Progressive MS



During ECTRIMS, Sanofi announced the results of its HERCULES phase 3 study in people with non-relapsing secondary progressive multiple sclerosis demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression by 31% compared to placebo.

Robert Fox, MD, Chair of the Alliance Scientific Steering Committee and Chair of the HERCULES Steering Committee, shared the results of this trial during the conference, saying this is encouraging since we don't currently have other therapies available for secondary progressive MS. [Click here](#) to see the full video with his commentary.